logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Axikin Pharmaceuticals, Inc.


USPTO Granted Patents = 23

% Expired Patents = 87.0



Forward Citations = 59

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Tai Wei Ly (18 out of 24 patents)

silverMedal Garrett Thomas Potter (11 out of 12 patents)

bronzeMedal Erik Dean Raaum (7 out of 8 patents)

4.  Kevin Bacon (5 out of 12 patents)

5.  Yingfu Li (4 out of 6 patents)

6.  Keiko Fukushima (4 out of 5 patents)

7.  Toshiya Moriwaki (4 out of 12 patents)

8.  Klaus Urbahns (4 out of 24 patents)

9.  Noriko Nunami (4 out of 5 patents)

10.  Jared Andrew Forrester (3 out of 3 patents)

11.  Timothy B Lowinger (2 out of 48 patents)

12.  Naoki Tsuno (2 out of 29 patents)

13.  Takashi Yoshino (2 out of 13 patents)

14.  Kentaro Hashimoto (2 out of 2 patents)

15.  Makiko Marumo (2 out of 3 patents)


23 patents:

1. 9730914 - 3,5-diaminopyrazole kinase inhibitors (2017-08-15),
2. 9637460 - Isotopically enriched arylsulfonamide CCR3 antagonists (2017-05-02),
3. 9546163 - 3,5-diaminopyrazole kinase inhibitors (2017-01-17),
4. 9540351 - Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors (2017-01-10),
5. 9382237 - 3,5-diaminopyrazole kinase inhibitors (2016-07-05),
6. 9365556 - 3,5-diaminopyrazole kinase inhibitors (2016-06-14),
7. 9346792 - 3,5-diaminopyrazole kinase inhibitors (2016-05-24),
8. 9206186 - 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders (2015-12-08),
9. 9187425 - 2,5-disubstituted arylsulfonamide CCR3 antagonists (2015-11-17),
10. 9156799 - Isotopically enriched arylsulfonamide CCR3 antagonists (2015-10-13),
11. 8999995 - Isotopically enriched arylsulfonamide CCR3 antagonists (2015-04-07),
12. 8916555 - 3,5-diaminopyrazole kinase inhibitors (2014-12-23),
13. 8741894 - Arylsulfonamide CCR3 antagonists (2014-06-03),
14. 8669247 - 2,5-disubstituted arylsulfonamide CCR3 antagonists (2014-03-11),
15. 8658642 - Arylsulfonamide CCR3 antagonists (2014-02-25),
Company Overview
Axikin Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for unmet medical needs. The company specializes in the research and development of novel treatments, particularly in the fields of oncology and autoimmune diseases. By leveraging advanced scientific methodologies and a commitment to improving patient outcomes, Axikin aims to bring transformative solutions to the healthcare landscape, addressing critical challenges in disease management and treatment efficacy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

23 Patents

#263 in San Diego, CA

#3,419 in California

#14,428 in US

#27,685 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Axikin Pharmaceuticals, Inc.

Forward Citations = 59

28 inventors:

goldMedal Tai Wei Ly (18 out of 24 patents)

silverMedal Garrett Thomas Potter (11 out of 12 patents)

bronzeMedal Erik Dean Raaum (7 out of 8 patents)

4.  Kevin Bacon (5 out of 12 patents)

5.  Yingfu Li (4 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Axikin Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/axikin-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…